Eli Lilly and Company (NYSE:LLY) is considered one of the best growth stocks to buy in 2026. Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating, citing successful obesity product launches and pipeline expansion. 2027 earnings are expected to reflect long-term growth potential.

Results from the Phase 3 EMBER-3 study for Inluriyo (imlunestrant) by Eli Lilly showed efficacy as standalone treatment and in combination with Verzenio (abemaciclib) for ER+, HER2- advanced breast cancer. Imlunestrant monotherapy reduced the risk of progression or death by 38%, with combination therapy showing even stronger results.

Eli Lilly submitted combination data for US regulatory review in ESR1-mutated metastatic breast cancer. Imlunestrant is also being studied in the EMBER-4 trial for early breast cancer treatment. The company operates in the US, Europe, China, Japan, and globally, focusing on human pharmaceuticals.

While Eli Lilly is recognized as a solid investment, some believe certain AI stocks offer greater growth potential and lower risk. Investors looking for undervalued AI stocks with potential benefits from tariffs and onshoring trends can explore other options. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches